{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:24:01Z","timestamp":1790659441218,"version":"4.1.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204454"],"award-info":[{"award-number":["82204454"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017379","name":"Beijing Engineering and Technology Research Center of Food Additives","doi-asserted-by":"publisher","award":["Y-MSDPU2022-0777"],"award-info":[{"award-number":["Y-MSDPU2022-0777"]}],"id":[{"id":"10.13039\/100017379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-QL202201-0021"],"award-info":[{"award-number":["Y-QL202201-0021"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Drug Safety Research Project by Adverse Drug Reactions Journal","award":["ADR2024MS24"],"award-info":[{"award-number":["ADR2024MS24"]}]},{"name":"Jiangsu Research Hospital Assocaiation for Precision Medication","award":["JY202044"],"award-info":[{"award-number":["JY202044"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12272-025-01583-9","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T08:32:29Z","timestamp":1763281949000},"page":"1177-1223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances and challenges of estrogen receptor-targeted agents in breast cancer"],"prefix":"10.1007","volume":"48","author":[{"given":"Jie","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-1198","authenticated-orcid":false,"given":"Wentong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"1583_CR1","doi-asserted-by":"publisher","unstructured":"L M, Shripad V, Zhao B, Shen W, Mur C, Barr R, Kindler LJ, Rubio A, Bastian JA, Cohen JD, Mattioni BE, Yuen E, Baker TK, Castanares MA, Fei D, Manro JR, Lallena MJ, Peng S-B, De Dios A (2021) Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD). Cancer Res 81:1236\u20131236. https:\/\/doi.org\/10.1158\/1538-7445.AM2021-1236.","DOI":"10.1158\/1538-7445.AM2021-1236"},{"key":"1583_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41467-019-14098-x","volume":"11","author":"J Achinger-Kawecka","year":"2020","unstructured":"Achinger-Kawecka J, Valdes-Mora F, Luu PL, Giles KA, Caldon CE, Qu W, Nair S, Soto S, Locke WJ, Yeo-Teh NS, Gould CM, Du Q, Smith GC, Ramos IR, Fernandez KF, Hoon DS, Gee JMW, Stirzaker C, Clark SJ (2020) Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer. Nat Commun 11:320. https:\/\/doi.org\/10.1038\/s41467-019-14098-x","journal-title":"Nat Commun"},{"key":"1583_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.259","volume":"33","author":"PG Aftimos","year":"2022","unstructured":"Aftimos PG, Cort\u00e9s J, Bidard FC, Kaklamani V, Bardia A, Neven P, Streich G, Montero A, Forget F, Mouret Reynier MA, Sohn J, Taylor D, Harnden K, Khong H, Kocsis J, Dalenc F, Dillon P, Tonini G, Grzegorzewski KJ, Lu J (2022) 220P elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+\/HER2- advanced\/metastatic breast cancer (mBC): subgroup analysis from EMERALD. Ann Oncol 33:S638. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.259","journal-title":"Ann Oncol"},{"key":"1583_CR4","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1021\/acs.biochem.1c00353","volume":"60","author":"S Alabi","year":"2021","unstructured":"Alabi S (2021) Novel mechanisms of molecular glue-induced protein degradation. Biochemistry 60:2371\u20132373. https:\/\/doi.org\/10.1021\/acs.biochem.1c00353","journal-title":"Biochemistry"},{"key":"1583_CR5","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, P\u00e1pai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"key":"1583_CR6","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1158\/1535-7163.Mct-19-1148","volume":"19","author":"KJ Andreano","year":"2020","unstructured":"Andreano KJ, Baker JG, Park S, Safi R, Artham S, Oesterreich S, Jeselsohn R, Brown M, Sammons S, Wardell SE, Chang CY, Norris JD, Mcdonnell DP (2020) The dysregulated pharmacology of clinically relevant ESR1 mutants is normalized by ligand-activated WT receptor. Mol Cancer Ther 19:1395\u20131405. https:\/\/doi.org\/10.1158\/1535-7163.Mct-19-1148","journal-title":"Mol Cancer Ther"},{"key":"1583_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10549-020-05575-9","volume":"180","author":"KJ Andreano","year":"2020","unstructured":"Andreano KJ, Wardell SE, Baker JG, Desautels TK, Baldi R, Chao CA, Heetderks KA, Bae Y, Xiong R, Tonetti DA, Gutgesell LM, Zhao J, Sorrentino JA, Thompson DA, Bisi JE, Strum JC, Thatcher GRJ, Norris JD (2020) G1T48, an oral selective estrogen receptor degrader, and the CDK4\/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Res Treat 180:635\u2013646. https:\/\/doi.org\/10.1007\/s10549-020-05575-9","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"1583_CR8","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1158\/1078-0432.Ccr-25-1198","volume":"31","author":"RD Baird","year":"2025","unstructured":"Baird RD, Bermejo De Las Heras B, Ruiz-Borrego M, Vaklavas C, Moreno I, Oliveira M, Armstrong A, Turner N, Incorvati J, Twelves C, Ciruelos E, Hamilton E, Patel MR, Kabos P, Ciardullo C, Klinowska T, Lindemann JPO, Mathewson AM, Morrow CJ, Sykes A, Yang J, Zhang B, Victoria I (2025) Camizestrant in combination with three globally approved CDK4\/6 inhibitors in women with ER+, HER2- advanced breast cancer: results from SERENA-1. Clin Cancer Res 31(20):4244\u20134254. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-1198","journal-title":"Clin Cancer Res"},{"issue":"7820","key":"1583_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","volume":"584","author":"SM Banik","year":"2020","unstructured":"Banik SM, Pedram K, Wisnovsky S, Ahn G, Riley NM, Bertozzi CR (2020) Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584(7820):291\u2013297. https:\/\/doi.org\/10.1038\/s41586-020-2545-9","journal-title":"Nature"},{"issue":"1","key":"1583_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31668-8","volume":"13","author":"A Bardia","year":"2022","unstructured":"Bardia A, Chandarlapaty S, Linden HM, Ulaner GA, Gosselin A, Cartot-Cotton S, Cohen P, Doroumian S, Paux G, Celanovic M, Pelekanou V, Ming JE, Tern\u00e8s N, Bouaboula M, Lee JS, Bauchet AL, Campone M (2022) AMEERA-1 phase 1\/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive\/HER2-negative advanced breast cancer. Nat Commun 13(1):4116. https:\/\/doi.org\/10.1038\/s41467-022-31668-8","journal-title":"Nat Commun"},{"key":"1583_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221083956","volume":"14","author":"A Bardia","year":"2022","unstructured":"Bardia A, Cortes J, Hurvitz SA, Delaloge S, Iwata H, Shao ZM, Kanagavel D, Cohen P, Liu Q, Cartot-Cotton S, Pelekanou V, O\u2019shaughnessy J (2022) AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+\/HER2- advanced breast cancer. Ther Adv Med Oncol 14:17588359221083956. https:\/\/doi.org\/10.1177\/17588359221083956","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"1583_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10549-022-06797-9","volume":"197","author":"A Bardia","year":"2023","unstructured":"Bardia A, Mayer I, Winer E, Linden HM, Ma CX, Parker BA, Bellet M, Arteaga CL, Cheeti S, Gates M, Chang CW, Fredrickson J, Spoerke JM, Moore HM, Giltnane J, Friedman LS, Chow Maneval E, Chan I, Jhaveri K (2023) The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR\u2009+\u2009\/HER2\u2009-) advanced\/metastatic breast cancer. Breast Cancer Res Treat 197(2):319\u2013331. https:\/\/doi.org\/10.1007\/s10549-022-06797-9","journal-title":"Breast Cancer Res Treat"},{"key":"1583_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM (2022) Protac targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21:181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6","journal-title":"Nat Rev Drug Discov"},{"issue":"28","key":"1583_CR14","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/jco.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, Garc\u00eda S\u00e1enz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cort\u00e9s J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A (2022) Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol 40(28):3246\u20133256. https:\/\/doi.org\/10.1200\/jco.22.00338","journal-title":"J Clin Oncol"},{"issue":"6","key":"1583_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"FC Bidard","year":"2025","unstructured":"Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, Mcclain S, He W, Klinowska T, Huang-Bartlett C, Turner NC (2025) First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med 393(6):569\u2013580. https:\/\/doi.org\/10.1056\/NEJMoa2502929","journal-title":"N Engl J Med"},{"key":"1583_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1127","volume":"41","author":"VF Borges","year":"2023","unstructured":"Borges VF, Chan A, Lin NU, Tonda ME, Shilkrut M, Alemany CA (2023) A phase 1b\/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and\/or metastatic estrogen receptor\u2013positive (ER+)\/HER2-negative (HER2-) breast cancer. J Clin Oncol 41:TPS1127-TPS1127. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS1127","journal-title":"J Clin Oncol"},{"key":"1583_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041656","author":"A Bo\u017eovi\u0107","year":"2021","unstructured":"Bo\u017eovi\u0107 A, Mandu\u0161i\u0107 V, Todorovi\u0107 L, Krajnovi\u0107 M (2021) Estrogen receptor beta: the promising biomarker and potential target in metastases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22041656","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1583_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01740-2","volume":"25","author":"M Campone","year":"2023","unstructured":"Campone M, Bidard FC, Neven P, Wang L, Ling B, Dong Y, Paux G, Herold C, De Giorgi U (2023) AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer. Breast Cancer Res 25(1):141. https:\/\/doi.org\/10.1186\/s13058-023-01740-2","journal-title":"Breast Cancer Res"},{"issue":"6","key":"1583_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2505725","volume":"393","author":"M Campone","year":"2025","unstructured":"Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, Zamagni C, Cui J, Cazzaniga M, Cil T, Jerzak KJ, Fuentes C, Yoshinami T, Rodriguez-Lescure A, Sezer A, Fontana A, Guarneri V, Molckovsky A, Mouret-Reynier MA, Demirci U, Zhang Y, Valota O, Lu DR, Martignoni M, Parameswaran J, Zhi X, Hamilton EP (2025) Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med 393(6):556\u2013568. https:\/\/doi.org\/10.1056\/NEJMoa2505725","journal-title":"N Engl J Med"},{"key":"1583_CR20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.2022.40.16_suppl.528","volume":"40","author":"M Campone","year":"2022","unstructured":"Campone M, Dong Y, Ling B, Wang L, Herold CI (2022) AMEERA-4: a preoperative window-of-opportunity (WOO) study to assess the pharmacodynamic (PD) activity of amcenestrant or letrozole in postmenopausal patients with ER+\/HER2\u2212 primary breast cancer. J Clin Oncol 40:528\u2013528. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.528","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1583_CR21","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/s0960-9776(19)31115-4","volume":"48","author":"R Caparica","year":"2019","unstructured":"Caparica R, Brand\u00e3o M, Piccart M (2019) Systemic treatment of patients with early breast cancer: recent updates and state of the art. Breast (Edinburgh, Scotland) 48(Suppl 1):S7-s20. https:\/\/doi.org\/10.1016\/s0960-9776(19)31115-4","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"1583_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.839005","volume":"13","author":"P Chen","year":"2022","unstructured":"Chen P, Li B, Ou-Yang L (2022) Role of estrogen receptors in health and disease. Front Endocrinol 13:839005. https:\/\/doi.org\/10.3389\/fendo.2022.839005","journal-title":"Front Endocrinol"},{"issue":"17","key":"1583_CR23","doi-asserted-by":"publisher","first-page":"12559","DOI":"10.1021\/acs.jmedchem.3c01186","volume":"66","author":"Z Chen","year":"2023","unstructured":"Chen Z, Hu B, Rej RK, Wu D, Acharyya RK, Wang M, Xu T, Lu J, Metwally H, Wang Y, Mceachern D, Bai L, Gersch CL, Wang M, Zhang W, Li Q, Wen B, Sun D, Rae JM, Wang S (2023) Discovery of ERD-3111 as a potent and orally efficacious estrogen receptor PROTAC degrader with strong antitumor activity. J Med Chem 66(17):12559\u201312585. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01186","journal-title":"J Med Chem"},{"key":"1583_CR24","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-PD13-02","volume":"83","author":"AM Chibly","year":"2023","unstructured":"Chibly AM, Fernando TM, Metcalfe C, Hafner M, Owusu-Manu G, Hurvitz S, Bardia A, Fasching PA, Park YH, Quiroga V, Steinseifer J, Perez-Moreno P, Moore HM (2023) Abstract PD13-02: PD13-02 exploratory gene expression analysis of coopERA breast cancer (BC): a study evaluating neoadjuvant giredestrant versus anastrozole alone and in combination with palbociclib in ER-positive, HER2-negative untreated early BC. Cancer Res 83:PD13-02-PD13-02. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-PD13-02","journal-title":"Cancer Res"},{"key":"1583_CR25","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1200\/jco.20.01139","volume":"39","author":"EM Ciruelos","year":"2021","unstructured":"Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, Andr\u00e9 F (2021) Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from SOLAR-1. J Clin Oncol 39:2005\u20132015. https:\/\/doi.org\/10.1200\/jco.20.01139","journal-title":"J Clin Oncol"},{"key":"1583_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076834","author":"L Clusan","year":"2023","unstructured":"Clusan L, Ferri\u00e8re F, Flouriot G, Pakdel F (2023) A basic review on estrogen receptor signaling pathways in breast cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24076834","journal-title":"Int J Mol Sci"},{"issue":"13","key":"1583_CR27","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2217\/fon-2016-0526","volume":"13","author":"RM Connolly","year":"2017","unstructured":"Connolly RM, Rudek MA, Piekarz R (2017) Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncol 13(13):1137\u20131148. https:\/\/doi.org\/10.2217\/fon-2016-0526","journal-title":"Future Oncol"},{"key":"1583_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101377","volume":"8","author":"J Cort\u00e9s","year":"2023","unstructured":"Cort\u00e9s J, Bidard FC, Bardia A, Kaklamani VG, Vlachaki I, Tonini G, Habboubi N, Aftimos PG (2023) 188O EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+\/HER2\u2212 advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy. ESMO Open 8:101377. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101377","journal-title":"ESMO Open"},{"key":"1583_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102569","volume":"117","author":"C Corti","year":"2023","unstructured":"Corti C, De Angelis C, Bianchini G, Malorni L, Giuliano M, Hamilton E, Jeselsohn R, Jhaveri K, Curigliano G, Criscitiello C (2023) Novel endocrine therapies: what is next in estrogen receptor positive, HER2 negative breast cancer? Cancer Treat Rev 117:102569. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102569","journal-title":"Cancer Treat Rev"},{"key":"1583_CR30","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1158\/1078-0432.Ccr-22-0305","volume":"28","author":"M Cristofanilli","year":"2022","unstructured":"Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, Demichele A, Loi S, Iwata H, O\u2019leary B, Andr\u00e9 F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean MJ, Turner NC (2022) Overall survival with palbociclib and fulvestrant in women with HR+\/HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study. Clin Cancer Res 28:3433\u20133442. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-0305","journal-title":"Clin Cancer Res"},{"key":"1583_CR31","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.annonc.2023.09.3103","volume":"34","author":"S Damodaran","year":"2023","unstructured":"Damodaran S, O\u2019sullivan CC, Elkhanany A, Anderson IC, Barve M, Blau S, Cherian MA, Peguero JA, Goetz MP, Plourde PV, Portman DJ, Moore HCF (2023) Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+\/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol 34:1131\u20131140. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3103","journal-title":"Ann Oncol"},{"key":"1583_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt337","volume":"106","author":"A Di Leo","year":"2014","unstructured":"Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M (2014) Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106:djt337. https:\/\/doi.org\/10.1093\/jnci\/djt337","journal-title":"J Natl Cancer Inst"},{"key":"1583_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.canlet.2021.05.030","volume":"517","author":"FI Dimitrakopoulos","year":"2021","unstructured":"Dimitrakopoulos FI, Kottorou A, Tzezou A (2021) Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer. Cancer Lett 517:55\u201365. https:\/\/doi.org\/10.1016\/j.canlet.2021.05.030","journal-title":"Cancer Lett"},{"key":"1583_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112369","volume":"136","author":"H Dong","year":"2024","unstructured":"Dong H, Zeng X, Xu J, He C, Sun Z, Liu L, Huang Y, Sun Z, Cao Y, Peng Z, Qiu YA, Yu T (2024) Advances in immune regulation of the G protein-coupled estrogen receptor. Int Immunopharmacol 136:112369. https:\/\/doi.org\/10.1016\/j.intimp.2024.112369","journal-title":"Int Immunopharmacol"},{"key":"1583_CR35","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.2147\/dddt.S380925","volume":"16","author":"T Downton","year":"2022","unstructured":"Downton T, Zhou F, Segara D, Jeselsohn R, Lim E (2022) Oral selective estrogen receptor degraders (SERDs) in breast cancer: advances, challenges, and current status. Drug Des Devel Ther 16:2933\u20132948. https:\/\/doi.org\/10.2147\/dddt.S380925","journal-title":"Drug Des Devel Ther"},{"key":"1583_CR36","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10549-020-05787-z","volume":"183","author":"AZ Dudek","year":"2020","unstructured":"Dudek AZ, Liu LC, Fischer JH, Wiley EL, Sachdev JC, Bleeker J, Hurley RW, Tonetti DA, Thatcher GRJ, Venuti RP, O\u2019regan RM (2020) Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4\/6 inhibitor therapy. Breast Cancer Res Treat 183:617\u2013627. https:\/\/doi.org\/10.1007\/s10549-020-05787-z","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1583_CR37","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1021\/acs.jmedchem.9b01293","volume":"63","author":"Y El-Ahmad","year":"2020","unstructured":"El-Ahmad Y, Tabart M, Halley F, Certal V, Thompson F, Filoche-Romm\u00e9 B, Gruss-Leleu F, Muller C, Brollo M, Fabien L, Loyau V, Bertin L, Richepin P, Pilorge F, Desmazeau P, Girardet C, Beccari S, Louboutin A, Lebourg G, Le-Roux J, Terrier C, Vall\u00e9e F, Steier V, Mathieu M, Rak A, Abecassis PY, Vicat P, Benard T, Bouaboula M, Sun F, Shomali M, Hebert A, Levit M, Cheng H, Courjaud A, Ginesty C, Perrault C, Garcia-Echeverria C, Mccort G, Schio L (2020) Discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a potent and selective estrogen receptor degrader (SERD) for the treatment of estrogen-receptor-positive breast cancer. J Med Chem 63(2):512\u2013528. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01293","journal-title":"J Med Chem"},{"key":"1583_CR38","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.bcp.2006.02.002","volume":"71","author":"A Escande","year":"2006","unstructured":"Escande A, Pillon A, Servant N, Cravedi JP, Larrea F, Muhn P, Nicolas JC, Cavaill\u00e8s V, Balaguer P (2006) Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochem Pharmacol 71:1459\u201369. https:\/\/doi.org\/10.1016\/j.bcp.2006.02.002","journal-title":"Biochem Pharmacol"},{"key":"1583_CR39","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00432-008-0354-x","volume":"134","author":"J Fan","year":"2008","unstructured":"Fan J, Yin WJ, Lu JS, Wang L, Wu J, Wu FY, Di GH, Shen ZZ, Shao ZM (2008) ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol 134:883\u201390. https:\/\/doi.org\/10.1007\/s00432-008-0354-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"1583_CR40","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.37161","author":"SW Fanning","year":"2018","unstructured":"Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lain\u00e9 M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL (2018) The SERM\/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. https:\/\/doi.org\/10.7554\/eLife.37161","journal-title":"Elife"},{"key":"1583_CR41","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12792","author":"SW Fanning","year":"2016","unstructured":"Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, Toy W, Green B, Panchamukhi S, Katzenellenbogen BS, Tajkhorshid E, Griffin PR, Shen Y, Chandarlapaty S, Katzenellenbogen JA, Greene GL (2016) Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. https:\/\/doi.org\/10.7554\/eLife.12792","journal-title":"Elife"},{"key":"1583_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073438","author":"P Ferrari","year":"2025","unstructured":"Ferrari P, Schiavone ML, Scatena C, Nicolini A (2025) Molecular mechanisms and therapeutic strategies to overcome resistance to endocrine therapy and CDK4\/6 inhibitors in advanced ER+\/HER2- breast cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26073438","journal-title":"Int J Mol Sci"},{"key":"1583_CR43","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.seminoncol.2023.08.002","volume":"50","author":"A Ferro","year":"2023","unstructured":"Ferro A, Generali D, Caffo O, Caldara A, De Lisi D, Dipasquale M, Lorenzi M, Monteverdi S, Fedele P, Ciribilli Y (2023) Oral selective estrogen receptor degraders (SERDs): the new emperors in breast cancer clinical practice? Semin Oncol 50:90\u2013101. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.08.002","journal-title":"Semin Oncol"},{"key":"1583_CR44","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/jco.2016.67.3061","volume":"34","author":"C Fribbens","year":"2016","unstructured":"Fribbens C, O\u2019leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC (2016) Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 34:2961\u20138. https:\/\/doi.org\/10.1200\/jco.2016.67.3061","journal-title":"J Clin Oncol"},{"key":"1583_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","volume":"116","author":"N Fuentes","year":"2019","unstructured":"Fuentes N, Silveyra P (2019) Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol 116:135\u2013170. https:\/\/doi.org\/10.1016\/bs.apcsb.2019.01.001","journal-title":"Adv Protein Chem Struct Biol"},{"key":"1583_CR46","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.Mct-21-0378","volume":"21","author":"C Furman","year":"2022","unstructured":"Furman C, Puyang X, Zhang Z, Wu ZJ, Banka D, Aithal KB, Albacker LA, Hao MH, Irwin S, Kim A, Montesion M, Moriarty AD, Murugesan K, Nguyen TV, Rimkunas V, Sahmoud T, Wick MJ, Yao S, Zhang X, Zeng H, Vaillancourt FH, Bolduc DM, Larsen N, Zheng GZ, Prajapati S, Zhu P, Korpal M (2022) Covalent ER\u03b1 antagonist H3B\u20136545 demonstrates encouraging preclinical activity in therapy-resistant breast cancer. Mol Cancer Ther 21:890\u2013902. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0378","journal-title":"Mol Cancer Ther"},{"key":"1583_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1448687","volume":"14","author":"Y Gao","year":"2024","unstructured":"Gao Y, Yu Y, Zhang M, Yu W, Kang L (2024) Mechanisms of endocrine resistance in hormone receptor-positive breast cancer. Front Oncol 14:1448687. https:\/\/doi.org\/10.3389\/fonc.2024.1448687","journal-title":"Front Oncol"},{"key":"1583_CR48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS616","volume":"41","author":"C Geyer","year":"2023","unstructured":"Geyer C, Bardia A, Harbeck N, Rimawi MF, Hurvitz SA, Martin M, Loi S, Saji S, Jung KH, Werutsky G, Stroyakovskiy D, L\u00f3pez-Valverde V, Davis M, Badovinac Crnjevic T, P\u00e9rez-Moreno PD, Schmid P (2023) lidERA breast cancer (BC): phase III adjuvant study of giredestrant vs. physician\u2019s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2\u2013 eBC). J Clin Oncol 41:TPS616-TPS616. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS616","journal-title":"J Clin Oncol"},{"key":"1583_CR49","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL (2024) Breast cancer statistics 2024. CA Cancer J Clin 74:477\u2013495. https:\/\/doi.org\/10.3322\/caac.21863","journal-title":"CA Cancer J Clin"},{"key":"1583_CR50","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.annonc.2023.09.3104","volume":"34","author":"MP Goetz","year":"2023","unstructured":"Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, Graff SL, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O\u2019connor T, Pluard TJ, Rugo HS, Sammons SL, Schwartzberg LS, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Gal-Yam EN (2023) Lasofoxifene versus fulvestrant for ER+\/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II elaine 1 trial. Ann Oncol 34:1141\u20131151. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3104","journal-title":"Ann Oncol"},{"key":"1583_CR51","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS19-PD7-06","volume":"80","author":"MP Goetz","year":"2020","unstructured":"Goetz MP, Suman VJ, Reid JM, Kuffel M, Buhrow SA, Mcgovern RM, Black J, Dockter T, Symmans WF, Liu MC, Hawse JR, Doroshow J, Storniolo AM, Collins JM, Streicher H, Ames MM, Ingle JN, Partridge A, Carey L (2020) Abstract PD7-06: a randomized phase II trial of tamoxifen versus Z-endoxifen HCL in postmenopausal women with metastatic estrogen receptor positive, HER2 negative breast cancer. Cancer Res 80:PD7-06-PD7-06. https:\/\/doi.org\/10.1158\/1538-7445.SABCS19-PD7-06","journal-title":"Cancer Res"},{"key":"1583_CR52","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/jco.2017.73.3246","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, Mcgovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN (2017) First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer. J Clin Oncol 35:3391\u20133400. https:\/\/doi.org\/10.1200\/jco.2017.73.3246","journal-title":"J Clin Oncol"},{"key":"1583_CR53","doi-asserted-by":"publisher","first-page":"6924","DOI":"10.18632\/oncotarget.24023","volume":"9","author":"S Guo","year":"2018","unstructured":"Guo S, Zhang C, Bratton M, Mottamal M, Liu J, Ma P, Zheng S, Zhong Q, Yang L, Wiese TE, Wu Y, Ellis MJ, Matossian M, Burow ME, Miele L, Houtman R, Wang G (2018) ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models. Oncotarget 9:6924\u20136937. https:\/\/doi.org\/10.18632\/oncotarget.24023","journal-title":"Oncotarget"},{"key":"1583_CR54","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT074","volume":"84","author":"E Hamilton","year":"2024","unstructured":"Hamilton E, Kim S-B, Lin NU, Awada A, Gil EC, Sanzo AD, Vallespir BP, Theall KP, Ibrahim N (2024) Abstract CT074: ELECTRA: an open-label, multicenter, phase 1b\/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC). Cancer Res 84:CT074-CT074. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-CT074","journal-title":"Cancer Res"},{"key":"1583_CR55","doi-asserted-by":"publisher","first-page":"S323","DOI":"10.1016\/j.annonc.2023.09.3100","volume":"34","author":"E Hamilton","year":"2023","unstructured":"Hamilton E, Loibl S, Niikura N, Rastogi P, Saini KS, Gioni I, Klinowska T, Mayer I, Stuart M, Syta E, Walding A, Bachelot T (2023) 354TiP a phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+\/HER2\u2013 early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1). Ann Oncol 34:S323\u2013S324. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3100","journal-title":"Ann Oncol"},{"key":"1583_CR56","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","volume":"35","author":"E Hamilton","year":"2024","unstructured":"Hamilton E, Oliveira M, Turner N, Garc\u00eda-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD (2024) A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol 35:707\u2013717. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.012","journal-title":"Ann Oncol"},{"key":"1583_CR57","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-PD13-08","volume":"82","author":"E Hamilton","year":"2022","unstructured":"Hamilton E, Vahdat L, Han HS, Ranciato J, Gedrich R, Keung CF, Chirnomas D, Hurvitz S (2022) Abstract PD13-08: first-in-human safety and activity of ARV-471, a novel PROTAC\u00ae estrogen receptor degrader, in ER+\/HER2- locally advanced or metastatic breast cancer. Cancer Res 82:PD13-08-PD13-08. https:\/\/doi.org\/10.1158\/1538-7445.SABCS21-PD13-08","journal-title":"Cancer Res"},{"issue":"1","key":"1583_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02049-y","volume":"27","author":"EP Hamilton","year":"2025","unstructured":"Hamilton EP, Patel MR, Borges VF, Meisel JL, Okera M, Alemany CA, Pluard TJ, Wesolowski R, Sabanathan D, Miller KD, Conlin AK, Mccarthy N, Shaw M, Tonda M, Shilkrut M, Lin NU (2025) Palazestrant, a novel oral complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), in patients with ER+\/HER2-\u2009advanced or metastatic breast cancer: phase 1\/2 study results. Breast Cancer Res 27(1):119. https:\/\/doi.org\/10.1186\/s13058-025-02049-y","journal-title":"Breast Cancer Res"},{"key":"1583_CR59","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae051","author":"GR Hancock","year":"2024","unstructured":"Hancock GR, Gertz J, Jeselsohn R, Fanning SW (2024) Estrogen receptor alpha mutations, truncations, heterodimers, and therapies. Endocrinology. https:\/\/doi.org\/10.1210\/endocr\/bqae051","journal-title":"Endocrinology"},{"key":"1583_CR60","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41523-022-00497-9","volume":"8","author":"GR Hancock","year":"2022","unstructured":"Hancock GR, Young KS, Hosfield DJ, Joiner C, Sullivan EA, Yildiz Y, Lain\u00e9 M, Greene GL, Fanning SW (2022) Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells. NPJ Breast Cancer 8:130. https:\/\/doi.org\/10.1038\/s41523-022-00497-9","journal-title":"NPJ Breast Cancer"},{"key":"1583_CR61","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS20-PS18-09","volume":"81","author":"W He","year":"2021","unstructured":"He W, Zhang H, Perkins L, Bouza L, Liu K, Qian Y, Fan J (2021) Abstract PS18-09: novel chimeric small molecule AC682 potently degrades estrogen receptor with oral anti-tumor efficacy superior to fulvestrant. Cancer Res 81:PS18-09-PS18-09. https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-PS18-09","journal-title":"Cancer Res"},{"key":"1583_CR62","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00026.2006","volume":"87","author":"N Heldring","year":"2007","unstructured":"Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Str\u00f6m A, Treuter E, Warner M, Gustafsson JA (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87:905\u201331. https:\/\/doi.org\/10.1152\/physrev.00026.2006","journal-title":"Physiol Rev"},{"key":"1583_CR63","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1158\/1538-7445.AM2020-4376","volume":"80","author":"L Hodges-Gallagher","year":"2020","unstructured":"Hodges-Gallagher L, Harmon CL, Sun R, Myles DC, Kushner P (2020) Abstract 4376: OP-1250, a complete estrogen receptor antagonist (CERAN) that shrinks estrogen receptor positive tumors and exhibits favorable pharmacokinetics. Cancer Res 80:4376\u20134376. https:\/\/doi.org\/10.1158\/1538-7445.AM2020-4376","journal-title":"Cancer Res"},{"key":"1583_CR64","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40265-023-01861-0","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023) Elacestrant: first approval. Drugs 83:555\u2013561. https:\/\/doi.org\/10.1007\/s40265-023-01861-0","journal-title":"Drugs"},{"key":"1583_CR65","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10549-023-07136-2","volume":"203","author":"B Hu","year":"2024","unstructured":"Hu B, Hu J (2024) Complete elimination of estrogen receptor \u03b1 by PROTAC estrogen receptor \u03b1 degrader ERD-148 in breast cancer cells. Breast Cancer Res Treat 203:383\u2013396. https:\/\/doi.org\/10.1007\/s10549-023-07136-2","journal-title":"Breast Cancer Res Treat"},{"key":"1583_CR66","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-PO3-05-08","volume":"84","author":"S Hurvitz","year":"2024","unstructured":"Hurvitz S, Schott A, Ma C, Nanda R, Zahrah G, Hunter N, Tan A, Telli M, Mesias JA, Jeselsohn R, Munster P, Zhi E, Duperret E, Mather C, Hamilton E, Han H (2024) Abstract PO3-05-08: updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER\u2013positive\/human epidermal growth factor receptor 2 (HER2)\u2013negative advanced breast cancer. Cancer Res 84:PO3-05-08-PO3-05-08. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-PO3-05-08","journal-title":"Cancer Res"},{"issue":"1","key":"1583_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01286-7","volume":"22","author":"S Jayaraman","year":"2020","unstructured":"Jayaraman S, Hou X, Kuffel MJ, Suman VJ, Hoskin TL, Reinicke KE, Monroe DG, Kalari KR, Tang X, Zeldenrust MA, Cheng J, Bruinsma ES, Buhrow SA, Mcgovern RM, Safgren SL, Walden CA, Carter JM, Reid JM, Ingle JN, Ames MM, Hawse JR, Goetz MP (2020) Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Res 22(1):51. https:\/\/doi.org\/10.1186\/s13058-020-01286-7","journal-title":"Breast Cancer Res"},{"key":"1583_CR68","doi-asserted-by":"publisher","first-page":"15197","DOI":"10.1073\/pnas.211556298","volume":"98","author":"EV Jensen","year":"2001","unstructured":"Jensen EV, Cheng G, Palmieri C, Saji S, M\u00e4kel\u00e4 S, Van Noorden S, Wahlstr\u00f6m T, Warner M, Coombes RC, Gustafsson JA (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A 98:15197\u2013202. https:\/\/doi.org\/10.1073\/pnas.211556298","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1583_CR69","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-PD1-05","volume":"79","author":"R Jeselsohn","year":"2019","unstructured":"Jeselsohn R, Guo H, Rees R, Barry WT, Barlett CH, Tung NM, Krop IE, Brown M, Winer EP (2019) Abstract PD1-05: results from the phase Ib\/II clinical trial of bazedoxifene and palbociclib in hormone receptor positive metastatic breast cancer. Cancer Res 79:PD1-05-PD1-05. https:\/\/doi.org\/10.1158\/1538-7445.SABCS18-PD1-05","journal-title":"Cancer Res"},{"key":"1583_CR70","doi-asserted-by":"publisher","first-page":"S338","DOI":"10.1016\/j.annonc.2023.09.560","volume":"34","author":"K Jhaveri","year":"2023","unstructured":"Jhaveri K, Jeselsohn R, Ma CX, Lim E, Yonemori K, Hamilton EP, Harnden K, Im SA, Beck T, Sammons S, Bhave M, Kaufman PA, Manich CS, Meniawy T, Bacchion F, Ismail-Khan R, Li Y, Estrem ST, Nguyen B, Beeram M (2023) 383MO imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): results from the phase Ia\/b EMBER study. Ann Oncol 34:S338\u2013S339. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.560","journal-title":"Ann Oncol"},{"key":"1583_CR71","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-OT1-01-02","volume":"83","author":"K Jhaveri","year":"2023","unstructured":"Jhaveri K, O\u2019shaughnessy J, Andre F, Goetz MP, Harbeck N, Mart\u00edn M, Bidard F-C, Thomas ZM, Young S, Ismail-Khan R, Smyth LM, Gnant M (2023) Abstract OT1-01-02: EMBER-4: a phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET. Cancer Res 83:OT1-01-02-OT1-01-02. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-OT1-01-02","journal-title":"Cancer Res"},{"key":"1583_CR72","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1200\/JCO.2021.39.15_suppl.1017","volume":"39","author":"KL Jhaveri","year":"2021","unstructured":"Jhaveri KL, Boni V, Sohn J, Villanueva-V\u00e1squez R, Bardia A, Schmid P, Lim E, Patel JM, Perez-Fidalgo JA, Loi S, Im S-A, Kshirsagar S, Gates MR, Bond J, Eng-Wong J, Chang C-W, Turner NC, Miranda EL, Garc\u00eda-Est\u00e9vez L, Bellet M (2021) Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia\/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced\/metastatic breast cancer (LA\/mBC). J Clin Oncol 39:1017\u20131017. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.1017","journal-title":"J Clin Oncol"},{"key":"1583_CR73","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1200\/jco.23.02733","volume":"42","author":"KL Jhaveri","year":"2024","unstructured":"Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, Bhave M, Kaufman PA, Beck JT, Manso Sanchez L, Parajuli R, Wang HC, Tao JJ, Im SA, Harnden K, Yonemori K, Dhakal A, Neven P, Aftimos P, Pierga JY, Lu YS, Larson T, Jerez Y, Sideras K, Sohn J, Kim SB, Saura C, Bardia A, Sammons SL, Bacchion F, Li Y, Yuen E, Estrem ST, Rodrik-Outmezguine V, Nguyen B, Ismail-Khan R, Smyth L, Beeram M (2024) Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: phase Ia\/Ib EMBER study. J Clin Oncol 42:4173\u20134186. https:\/\/doi.org\/10.1200\/jco.23.02733","journal-title":"J Clin Oncol"},{"key":"1583_CR74","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O\u2019shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E, Garc\u00eda Tinoco ML, Sohn J, Mattar A, Zhang Q, Huang CS, Hung CC, Martinez Rodriguez JL, Ru\u00edz Borrego M, Nakamura R, Pradhan KR, Cramer Von Laue C, Barrett E, Cao S, Wang XA, Smyth LM, Bidard FC (2025) Imlunestrant with or without Abemaciclib in advanced breast cancer. N Engl J Med 392:1189\u20131202. https:\/\/doi.org\/10.1056\/NEJMoa2410858","journal-title":"N Engl J Med"},{"key":"1583_CR75","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.bbrc.2017.06.117","volume":"490","author":"AM Jim\u00e9nez-Gardu\u00f1o","year":"2017","unstructured":"Jim\u00e9nez-Gardu\u00f1o AM, Mendoza-Rodr\u00edguez MG, Urrutia-Cabrera D, Dom\u00ednguez-Robles MC, P\u00e9rez-Y\u00e9pez EA, Ayala-Sumuano JT, Meza I (2017) IL-1\u03b2 induced methylation of the estrogen receptor ER\u03b1 gene correlates with EMT and chemoresistance in breast cancer cells. Biochem Biophys Res Commun 490:780\u2013785. https:\/\/doi.org\/10.1016\/j.bbrc.2017.06.117","journal-title":"Biochem Biophys Res Commun"},{"key":"1583_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.572","volume":"34","author":"KH Jung","year":"2023","unstructured":"Jung KH, Luen SJ, Oliveira M, Sohn J, Im SA, Wander S, Hurvitz SA, Sonnenblick A, Breton V, Collier A, Deb S, Ngo H, Schwab R, Shemesh C, Zhu J, Melia CH (2023) 395P interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): a phase I\/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced\/metastatic BC (LA\/mBC). Ann Oncol 34:S347. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.572","journal-title":"Ann Oncol"},{"key":"1583_CR77","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/2472555221991104","volume":"26","author":"JM Kastl","year":"2021","unstructured":"Kastl JM, Davies G, Godsman E, Holdgate GA (2021) Small-molecule degraders beyond PROTACs-challenges and opportunities. SLAS Discov 26:524\u2013533. https:\/\/doi.org\/10.1177\/2472555221991104","journal-title":"SLAS Discov"},{"key":"1583_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114658","volume":"241","author":"MZI Khan","year":"2022","unstructured":"Khan MZI, Uzair M, Nazli A, Chen JZ (2022) An overview on estrogen receptors signaling and its ligands in breast cancer. Eur J Med Chem 241:114658. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114658","journal-title":"Eur J Med Chem"},{"key":"1583_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081575","author":"JK Kranj\u010devi\u0107","year":"2024","unstructured":"Kranj\u010devi\u0107 JK, \u010conka\u0161 J, Ozreti\u0107 P (2024) The role of estrogen and estrogen receptors in head and neck tumors. Cancers. https:\/\/doi.org\/10.3390\/cancers16081575","journal-title":"Cancers"},{"key":"1583_CR80","first-page":"5887","volume":"60","author":"H Kurokawa","year":"2000","unstructured":"Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL (2000) Inhibition of HER2\/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60:5887\u201394","journal-title":"Cancer Res"},{"key":"1583_CR81","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/jnci\/djq415","volume":"102","author":"AZ Lacroix","year":"2010","unstructured":"Lacroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, Allred DC, Armstrong R, Cummings SR, Eastell R, Ensrud KE, Goss P, Lee A, Neven P, Reid DM, Curto M, Vukicevic S (2010) Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 102:1706\u201315. https:\/\/doi.org\/10.1093\/jnci\/djq415","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1583_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01431-w","volume":"23","author":"M Lain\u00e9","year":"2021","unstructured":"Lain\u00e9 M, Fanning SW, Chang YF, Green B, Greene ME, Komm B, Kurleto JD, Phung L, Greene GL (2021) Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res 23(1):54. https:\/\/doi.org\/10.1186\/s13058-021-01431-w","journal-title":"Breast Cancer Res"},{"key":"1583_CR83","unstructured":"Lawson, M a-O, Cureton, N a-O, Ros, S a-O, Cheraghchi-Bashi, A a-O, Urosevic, J a-O, D'arcy, S a-O, Delpuech, O a-O X, Dupont, M a-O, Fisher, D a-O, Gangl, E a-O, Lewis, H a-O, Trueman, D a-O, Wali, N a-O, Williamson, S a-O, Moss, J a-O X, Montaudon, E a-O, Derrien, H a-O, Marangoni, E a-O, Miragaia, R a-O X, Gagrica, S a-O, Morentin-Gutierrez, P a-O, Moss, T a-O, Maglennon, G a-O, Sutton, D a-O, Polanski, R a-O X, Rosen, A a-O, Cairns, J a-O, Zhang, P a-O, S\u00e1nchez-Guix\u00e9, M a-O, Serra, V a-O, Critchlow, S a-O, Scott, J a-O, Lindemann, J a-O, Barry, S a-O, Klinowska, T a-O, Morrow, C a-O, and Carnevalli, L a-O The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4\/6 Inhibitor Resistance."},{"key":"1583_CR84","doi-asserted-by":"publisher","first-page":"134","DOI":"10.4143\/crt.2023.652","volume":"56","author":"X Li","year":"2024","unstructured":"Li X, Li Z, Li L, Liu T, Qian C, Ren Y, Li Z, Chen K, Ji D, Zhang M, Wang J (2024) Toremifene, an alternative adjuvant endocrine therapy, is better than tamoxifen in breast cancer patients with CYP2D6*10 mutant genotypes. Cancer Res Treatment 56:134\u2013142. https:\/\/doi.org\/10.4143\/crt.2023.652","journal-title":"Cancer Res Treatment"},{"key":"1583_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-024-01364-y","volume":"46","author":"YY Li","year":"2025","unstructured":"Li YY, Yang Y, Zhang RS, Ge RX, Xie SB (2025) Targeted degradation of membrane and extracellular proteins with LYTACs. Acta Pharmacol Sin 46:1\u20137. https:\/\/doi.org\/10.1038\/s41401-024-01364-y","journal-title":"Acta Pharmacol Sin"},{"key":"1583_CR86","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1021\/acsmedchemlett.0c00224","volume":"11","author":"J Liang","year":"2020","unstructured":"Liang J, Blake R, Chang J, Friedman LS, Goodacre S, Hartman S, Ingalla ER, Kiefer JR, Kleinheinz T, Labadie S, Li J, Lai KW, Liao J, Mody V, Mclean N, Metcalfe C, Nannini M, Otwine D, Ran Y, Ray N, Roussel F, Sambrone A, Sampath D, Vinogradova M, Wai J, Wang T, Yeap K, Young A, Zbieg J, Zhang B, Zheng X, Zhong Y, Wang X (2020) Discovery of GNE-149 as a full antagonist and efficient degrader of estrogen receptor alpha for ER+ breast cancer. ACS Med Chem Lett 11:1342\u20131347. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00224","journal-title":"ACS Med Chem Lett"},{"key":"1583_CR87","doi-asserted-by":"publisher","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","volume":"64","author":"J Liang","year":"2021","unstructured":"Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, Dipasquale AG, Friedman LS, Gelzleichter T, Gill M, Giltnane JM, Goodacre S, Guan J, Hartman SJ, Ingalla ER, Kategaya L, Kiefer JR, Kleinheinz T, Labadie SS, Lai T, Li J, Liao J, Liu Z, Mody V, Mclean N, Metcalfe C, Nannini MA, Oeh J, O\u2019rourke MG, Ortwine DF, Ran Y, Ray NC, Roussel F, Sambrone A, Sampath D, Schutt LK, Vinogradova M, Wai J, Wang T, Wertz IE, White JR, Yeap SK, Young A, Zhang B, Zheng X, Zhou W, Zhong Y, Wang X (2021) GDC-9545 (giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer. J Med Chem 64:11841\u201311856. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00847","journal-title":"J Med Chem"},{"issue":"15_suppl","key":"1583_CR88","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1200\/JCO.2020.38.15_suppl.1023","volume":"38","author":"E Lim","year":"2020","unstructured":"Lim E, Jhaveri KL, Perez-Fidalgo JA, Bellet M, Boni V, Perez Garcia JM, Estevez L, Bardia A, Turner NC, Villanueva R, Lopez-Tarruella Cobo S, Im S-A, Kim S-B, Gates MR, Monemi S, Chen Y-C, Moore H, Loi S, Sohn J (2020) A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. J Clin Oncol 38(15_suppl):1023\u20131023. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.1023","journal-title":"J Clin Oncol"},{"key":"1583_CR89","doi-asserted-by":"publisher","first-page":"8134","DOI":"10.1021\/acs.jmedchem.6b00753","volume":"59","author":"J Liu","year":"2016","unstructured":"Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q, Zhang C, Zhang Q, Guo S, Ma P, Skripnikova EV, Bratton MR, Pannuti A, Miele L, Wiese TE, Wang G (2016) Fulvestrant-3 boronic acid (ZB716): an orally bioavailable selective estrogen receptor downregulator (SERD). J Med Chem 59:8134\u201340. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00753","journal-title":"J Med Chem"},{"key":"1583_CR90","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.2147\/ott.S236532","volume":"13","author":"Y Liu","year":"2020","unstructured":"Liu Y, Ma H, Yao J (2020) ER\u03b1, a key target for cancer therapy: a review. Onco Targets Ther 13:2183\u20132191. https:\/\/doi.org\/10.2147\/ott.S236532","journal-title":"Onco Targets Ther"},{"key":"1583_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113247","volume":"216","author":"Z Ma","year":"2021","unstructured":"Ma Z, Ji Y, Yu Y, Liang D (2021) Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy. Eur J Med Chem 216:113247. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113247","journal-title":"Eur J Med Chem"},{"key":"1583_CR92","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-3-031-33602-7_9","volume":"188","author":"A Marra","year":"2023","unstructured":"Marra A, Trapani D, Ferraro E, Curigliano G (2023) Mechanisms of endocrine resistance in hormone receptor-positive breast cancer. Cancer Treat Res 188:219\u2013235. https:\/\/doi.org\/10.1007\/978-3-031-33602-7_9","journal-title":"Cancer Treat Res"},{"issue":"6","key":"1583_CR93","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40291-025-00811-8","volume":"29","author":"S Martella","year":"2025","unstructured":"Martella S, Cusumano G, Senevirathne TH, Stylianakis D, Palmas E, Denaro N, Tommasi C, Scartozzi M, Gerratana L, Solinas C (2025) Evolutionary overview and future perspectives: ESR1 mutations, liquid biopsy, and artificial intelligence for a new era of personalized medicine in ER+ breast cancer. Mol Diagn Ther 29(6):773\u2013787. https:\/\/doi.org\/10.1007\/s40291-025-00811-8","journal-title":"Mol Diagn Ther"},{"key":"1583_CR94","doi-asserted-by":"publisher","first-page":"S633","DOI":"10.1016\/j.annonc.2022.07.250","volume":"33","author":"M Martin Jimenez","year":"2022","unstructured":"Martin Jimenez M, Lim E, Chavez Mac Gregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz F, Safin R, Kim SB, Schem C, Montero A, Khan S, Bandyopadhyay R, Shivhare M, Patre M, Martinalbo J, Roncoroni L, P\u00e9rez-Moreno PD, Sohn JH (2022) 211MO giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2\u2013 locally advanced\/metastatic breast cancer (LA\/mBC): primary analysis of the phase II, randomised, open-label acelERA BC study. Ann Oncol 33:S633\u2013S634","journal-title":"Ann Oncol"},{"key":"1583_CR95","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1200\/jco.23.01500","volume":"42","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Lim E, Chavez-Macgregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim SB, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, P\u00e9rez-Moreno PD, Sohn J (2024) Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study. J Clin Oncol 42:2149\u20132160. https:\/\/doi.org\/10.1200\/jco.23.01500","journal-title":"J Clin Oncol"},{"key":"1583_CR96","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1021\/acs.jmedchem.2c01882","volume":"66","author":"IN Michaelides","year":"2023","unstructured":"Michaelides IN, Collie GW (2023) E3 ligases meet their match: fragment-based approaches to discover new E3 ligands and to unravel E3 biology. J Med Chem 66:3173\u20133194. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01882","journal-title":"J Med Chem"},{"key":"1583_CR97","doi-asserted-by":"publisher","first-page":"57","DOI":"10.15212\/amm-2024-0006","volume":"3","author":"J Min","year":"2024","unstructured":"Min J, Liu X, Peng R, Chen C-C, Wang W, Guo R-T (2024) New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives. Acta Mater Med 3:57\u201371. https:\/\/doi.org\/10.15212\/amm-2024-0006","journal-title":"Acta Mater Med"},{"key":"1583_CR98","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/JCO.2021.39.15_suppl.577","volume":"39","author":"HM Moore","year":"2021","unstructured":"Moore HM, Boni V, Bellet M, De Las Bermejo, Heras B, Gi\u00f3n Cort\u00e9s M, Oakman C, Schmid P, Trinh XB, Wheatley D, Jhaveri KL, Kabos P, Lim E, Velu T, Metcalfe C, Gates MR, Chang C-W, Bond J, Goldstein LD, Lauchle JOH, Bardia A (2021) Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+\/HER2\u2013) operable breast cancer (BC). J Clin Oncol 39:577\u2013577. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.577","journal-title":"J Clin Oncol"},{"key":"1583_CR99","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49079","volume":"15","author":"G Motlani","year":"2023","unstructured":"Motlani G, Motlani V, Acharya N, Dave A, Pamnani S, Somyani D, Agrawal S (2023) Novel advances in the role of selective estrogen receptor modulators in hormonal replacement therapy: a paradigm shift. Cureus 15:e49079. https:\/\/doi.org\/10.7759\/cureus.49079","journal-title":"Cureus"},{"key":"1583_CR100","doi-asserted-by":"publisher","first-page":"9334","DOI":"10.1021\/acsomega.0c06362","volume":"6","author":"M Mottamal","year":"2021","unstructured":"Mottamal M, Kang B, Peng X, Wang G (2021) From pure antagonists to pure degraders of the estrogen receptor: evolving strategies for the same target. ACS Omega 6:9334\u20139343. https:\/\/doi.org\/10.1021\/acsomega.0c06362","journal-title":"ACS Omega"},{"key":"1583_CR101","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2174\/092986707780598023","volume":"14","author":"MA Musa","year":"2007","unstructured":"Musa MA, Khan MO, Cooperwood JS (2007) Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr Med Chem 14:1249\u201361. https:\/\/doi.org\/10.2174\/092986707780598023","journal-title":"Curr Med Chem"},{"key":"1583_CR102","doi-asserted-by":"publisher","unstructured":"Nagel YA, Britschgi A, Ricci A (2021) From degraders to molecular glues: new ways of breaking down disease-associated proteins. Successful Drug Discovery, pp\u00a047\u201385.https:\/\/doi.org\/10.1002\/9783527826872.ch2.","DOI":"10.1002\/9783527826872.ch2"},{"key":"1583_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1037531","volume":"12","author":"Z Nagy","year":"2022","unstructured":"Nagy Z, Jeselsohn R (2022) ESR1 fusions and therapeutic resistance in metastatic breast cancer. Front Oncol 12:1037531. https:\/\/doi.org\/10.3389\/fonc.2022.1037531","journal-title":"Front Oncol"},{"key":"1583_CR104","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s12672-015-0230-5","volume":"6","author":"SR Nayak","year":"2015","unstructured":"Nayak SR, Harrington E, Boone D, Hartmaier R, Chen J, Pathiraja TN, Cooper KL, Fine JL, Sanfilippo J, Davidson NE, Lee AV, Dabbs D, Oesterreich S (2015) A role for histone H2B variants in endocrine-resistant breast cancer. Hormones Cancer 6:214\u201324. https:\/\/doi.org\/10.1007\/s12672-015-0230-5","journal-title":"Hormones Cancer"},{"key":"1583_CR105","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"CGA Network","year":"2012","unstructured":"Network CGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61\u201370. https:\/\/doi.org\/10.1038\/nature11412","journal-title":"Nature"},{"issue":"23","key":"1583_CR106","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1158\/1078-0432.Ccr-24-2113","volume":"30","author":"P Neven","year":"2024","unstructured":"Neven P, Stahl N, Vidal M, Mart\u00edn M, Kaufman PA, Harbeck N, Hunt KK, Carter S, Bidard FC, Fasching PA, Aftimos P, Wheatley D, Hamilton E, Aft R, Kulkarni S, Schmid P, Bhave M, Ismail-Khan R, Karacsonyi C, Estrem ST, Nguyen B, Ozbek U, Yuen E, Rodrik-Outmezguine V, Ciruelos E (2024) A preoperative window-of-opportunity study of oral SERD, Imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: results from the EMBER-2 study. Clin Cancer Res 30(23):5304\u20135313. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-2113","journal-title":"Clin Cancer Res"},{"key":"1583_CR107","doi-asserted-by":"publisher","first-page":"S370","DOI":"10.1016\/j.annonc.2024.08.313","volume":"35","author":"M Oliveira","year":"2024","unstructured":"Oliveira M, Cortes MG, Jung KH, Bermejo B, Hurvitz SA, Sadeghi S, Wander S, Im SA, Gal-Yam E, Zhu J, Schwab R, Ngo H, Collier A, Cannon M, Cahuzac C, Moreno PDP, Mcintosh S, Serrano CS, Sonnenblick A (2024) 365P interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): a phase I\/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced\/metastatic BC (LA\/mBC). Ann Oncol 35:S370\u2013S371. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.313","journal-title":"Ann Oncol"},{"issue":"11","key":"1583_CR108","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/s1470-2045(24)00387-5","volume":"25","author":"M Oliveira","year":"2024","unstructured":"Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, Hotko Y, Melkadze T, Nemsadze G, Neven P, Vladimirov V, Zamagni C, Denys H, Forget F, Horvath Z, Nesterova A, Ajimi M, Kirova B, Klinowska T, Lindemann JPO, Lissa D, Mathewson A, Morrow CJ, Traugottova Z, Van Zyl R, Arkania E (2024) Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 25(11):1424\u20131439. https:\/\/doi.org\/10.1016\/s1470-2045(24)00387-5","journal-title":"Lancet Oncol"},{"key":"1583_CR109","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2023.41.16_suppl.1061","volume":"41","author":"M Oliveira","year":"2023","unstructured":"Oliveira M, Sonnenblick A, Rugo HS, Jung KH, Yam EG, Hurvitz SA, Hernando C, Im S-A, Breton V, Collier A, Schwab RB, Zhu J, Sohn J (2023) Interim analyses (IA) of the giredestrant (G), G + abemaciclib (A), and G + ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I\/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced\/metastatic BC (ER+, HER2\u2013 LA\/mBC). J Clin Oncol 41:1061\u20131061. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.1061","journal-title":"J Clin Oncol"},{"key":"1583_CR110","doi-asserted-by":"crossref","unstructured":"Osborne C, Richards DA, Wilks ST, Diab S, Hamilton EP (2021) Abstract PS11-26: a phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer. Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8\u201311, 2020; San Antonio, Texas,","DOI":"10.1158\/1538-7445.SABCS20-PS11-26"},{"key":"1583_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103861","volume":"180","author":"M Pagliuca","year":"2022","unstructured":"Pagliuca M, Donato M, D\u2019amato AL, Rosanova M, Russo AOM, Scafetta R, De Angelis C, Trivedi MV, Andr\u00e9 F, Arpino G, Del Mastro L, De Laurentiis M, Puglisi F, Giuliano M (2022) New steps on an old path: novel estrogen receptor inhibitors in breast cancer. Crit Rev Oncol Hematol 180:103861. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103861","journal-title":"Crit Rev Oncol Hematol"},{"key":"1583_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122700","author":"M Palaniappan","year":"2024","unstructured":"Palaniappan M (2024) Current therapeutic opportunities for estrogen receptor mutant breast cancer. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12122700","journal-title":"Biomedicines"},{"key":"1583_CR113","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-P2-24-07","volume":"83","author":"AD Parisian","year":"2023","unstructured":"Parisian AD, Palanisamy GS, Ortega F, Sapugay JL, Bodell WJ, Kulp D, Kushner P, Harmon C (2023) Abstract P2-24-07: combination of complete estrogen receptor antagonist, OP-1250, and CDK4\/6 inhibitors enhances tumor suppression and inhibition of cell cycle-related gene expression. Cancer Res 83:P2-24-07-P2-24-07. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-P2-24-07","journal-title":"Cancer Res"},{"key":"1583_CR114","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-P1-17-12","volume":"82","author":"M Patel","year":"2022","unstructured":"Patel M, Alemany C, Mitri Z, Makower D, Borges V, Sparano J, Le T, Klein P, Lawrence J, Kushner P, Faltaos D, Harmon C, Myles D, Zujewski J, Hamilton E (2022) Abstract P1-17-12: preliminary data from a phase I\/II, multicenter, dose escalation study of OP-1250, an oral CERAN\/SERD, in subjects with advanced and\/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer. Cancer Res 82:P1-17-12-P1-17-12. https:\/\/doi.org\/10.1158\/1538-7445.SABCS21-P1-17-12","journal-title":"Cancer Res"},{"key":"1583_CR115","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1200\/JCO.2024.42.16_suppl.3074","volume":"42","author":"MR Patel","year":"2024","unstructured":"Patel MR, Layman RM, Danso MA, Cosgrove D, Zettler ME, Pehlivan KC, Hamilton EP (2024) Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer. J Clin Oncol 42:3074\u20133074. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3074","journal-title":"J Clin Oncol"},{"key":"1583_CR116","doi-asserted-by":"publisher","DOI":"10.1039\/d4md00961d","author":"R Peng","year":"2024","unstructured":"Peng R, Liu X, Chen CC, Guo RT, Min J (2024) Development of PROTACs targeting estrogen receptor: an emerging technique for combating endocrine resistance. RSC Med Chem. https:\/\/doi.org\/10.1039\/d4md00961d","journal-title":"RSC Med Chem"},{"key":"1583_CR117","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/2053369115599090","volume":"21","author":"JH Pickar","year":"2015","unstructured":"Pickar JH, Komm BS (2015) Selective estrogen receptor modulators and the combination therapy conjugated estrogens\/bazedoxifene: a review of effects on the breast. Post Reprod Health 21:112\u201321. https:\/\/doi.org\/10.1177\/2053369115599090","journal-title":"Post Reprod Health"},{"key":"1583_CR118","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/13697137.2019.1568403","volume":"22","author":"JV Pinkerton","year":"2019","unstructured":"Pinkerton JV, Conner EA (2019) Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. Climacteric 22:140\u2013147. https:\/\/doi.org\/10.1080\/13697137.2019.1568403","journal-title":"Climacteric"},{"key":"1583_CR119","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.2174\/0929867328666211110101018","volume":"29","author":"H Qin","year":"2022","unstructured":"Qin H, Zhang Y, Lou Y, Pan Z, Song F, Liu Y, Xu T, Zheng X, Hu X, Huang P (2022) Overview of PROTACs targeting the estrogen receptor: achievements for biological and drug discovery. Curr Med Chem 29:3922\u20133944. https:\/\/doi.org\/10.2174\/0929867328666211110101018","journal-title":"Curr Med Chem"},{"key":"1583_CR120","volume-title":"Raloxifene","author":"BS Quintanilla Rodriguez","year":"2024","unstructured":"Quintanilla Rodriguez BS, Correa R (2024) Raloxifene. StatPearls. StatPearls Publishing, Tresure Island"},{"key":"1583_CR121","unstructured":"Copyright \u00a9 2024, StatPearls Publishing LLC., Treasure Island (FL) relationships with ineligible companies. Disclosure: Ricardo Correa declares no relevant financial relationships with ineligible companies.,"},{"issue":"22","key":"1583_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216198","volume":"24","author":"F Raheem","year":"2023","unstructured":"Raheem F, Karikalan SA, Batalini F, El Masry A, Mina L (2023) Metastatic ER+ breast cancer: mechanisms of resistance and future therapeutic approaches. Int J Mol Sci 24(22):16198. https:\/\/doi.org\/10.3390\/ijms242216198","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1583_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030552","volume":"16","author":"RK Rej","year":"2024","unstructured":"Rej RK, Roy J, Allu SR (2024) Therapies for the treatment of advanced\/metastatic estrogen receptor-positive breast cancer: current situation and future directions. Cancers 16(3):552. https:\/\/doi.org\/10.3390\/cancers16030552","journal-title":"Cancers"},{"key":"1583_CR124","doi-asserted-by":"publisher","first-page":"8339","DOI":"10.1021\/acs.jmedchem.3c00136","volume":"66","author":"RK Rej","year":"2023","unstructured":"Rej RK, Thomas JE 2nd, Acharyya RK, Rae JM, Wang S (2023) Targeting the estrogen receptor for the treatment of breast cancer: recent advances and challenges. J Med Chem 66:8339\u20138381. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00136","journal-title":"J Med Chem"},{"key":"1583_CR125","doi-asserted-by":"publisher","first-page":"RF01-01","DOI":"10.1158\/1538-7445.SABCS23-RF01-01","volume":"84","author":"J Robertson","year":"2024","unstructured":"Robertson J, Gogitidze T, Katashvili Z, Rocha JEB, Arkania E, Moppett I, Cheung K-L, Nemsadze G, Ajimi M, Irurzun-Arana I, Lindemann J, Klinowska T, Mathewson A, Morrow C, Nikolaou M, Dzagnidze G (2024) Abstract RF01-01: SERENA-3: a randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer. Cancer Res 84:RF01-01-RF01-01. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-RF01-01","journal-title":"Cancer Res"},{"key":"1583_CR126","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1200\/jco.2008.21.1136","volume":"27","author":"JF Robertson","year":"2009","unstructured":"Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J, Ellis MJ (2009) Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 27:4530\u20135. https:\/\/doi.org\/10.1200\/jco.2008.21.1136","journal-title":"J Clin Oncol"},{"key":"1583_CR127","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1016\/s0140-6736(16)32389-3","volume":"388","author":"JFR Robertson","year":"2016","unstructured":"Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ (2016) Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet (London, England) 388:2997\u20133005. https:\/\/doi.org\/10.1016\/s0140-6736(16)32389-3","journal-title":"Lancet (London, England)"},{"key":"1583_CR128","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1074\/jbc.275.6.4475","volume":"275","author":"BG Rowan","year":"2000","unstructured":"Rowan BG, Weigel NL, O\u2019malley BW (2000) Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem 275:4475\u201383. https:\/\/doi.org\/10.1074\/jbc.275.6.4475","journal-title":"J Biol Chem"},{"key":"1583_CR129","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","volume":"2","author":"KM Sakamoto","year":"2003","unstructured":"Sakamoto KM, Kim KB, Verma R, Ransick A, Stein B, Crews CM, Deshaies RJ (2003) Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol Cell Proteomics 2:1350\u20138. https:\/\/doi.org\/10.1074\/mcp.T300009-MCP200","journal-title":"Mol Cell Proteomics"},{"key":"#cr-split#-1583_CR130.1","doi-asserted-by":"crossref","unstructured":"Samatar AA, Li J, Hegde S, Huang P, Sergeeva M (2020) Abstract 4373: discovery of ZN-c5, a novel potent and oral selective estrogen receptor degrader. In: Proceedings: AACR Annual Meeting 2020","DOI":"10.1158\/1538-7445.AM2020-4373"},{"key":"#cr-split#-1583_CR130.2","unstructured":"April 27-28, 2020 and June 22-24, Philadelphia, PA"},{"key":"1583_CR131","doi-asserted-by":"publisher","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554. https:\/\/doi.org\/10.1126\/science.1096502","journal-title":"Science"},{"key":"1583_CR132","doi-asserted-by":"publisher","first-page":"14530","DOI":"10.1021\/acs.jmedchem.0c01163","volume":"63","author":"JS Scott","year":"2020","unstructured":"Scott JS, Moss TA, Balazs A, Barlaam B, Breed J, Carbajo RJ, Chiarparin E, Davey PRJ, Delpuech O, Fawell S, Fisher DI, Gagrica S, Gangl ET, Grebe T, Greenwood RD, Hande S, Hatoum-Mokdad H, Herlihy K, Hughes S, Hunt TA, Huynh H, Janbon SLM, Johnson T, Kavanagh S, Klinowska T, Lawson M, Lister AS, Marden S, Mcginnity DF, Morrow CJ, Nissink JWM, O\u2019donovan DH, Peng B, Polanski R, Stead DS, Stokes S, Thakur K, Throner SR, Tucker MJ, Varnes J, Wang H, Wilson DM, Wu D, Wu Y, Yang B, Yang W (2020) Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist. J Med Chem 63:14530\u201314559. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01163","journal-title":"J Med Chem"},{"key":"1583_CR133","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1021\/acsmedchemlett.0c00505","volume":"11","author":"JS Scott","year":"2020","unstructured":"Scott JS, Moss TA, Barlaam B, Davey PRJ, Fairley G, Gangl ET, Greenwood RDR, Hatoum-Mokdad H, Lister AS, Longmire D, Polanski R, Stokes S, Tucker MJ, Varnes JG, Yang B (2020) Addition of Fluorine and a Late-Stage Functionalization (LSF) of the Oral SERD AZD9833. ACS Med Chem Lett 11:2519\u20132525. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00505","journal-title":"ACS Med Chem Lett"},{"key":"1583_CR134","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1200\/jco.23.02112","volume":"42","author":"M Shah","year":"2024","unstructured":"Shah M, Lingam H, Gao X, Gittleman H, Fiero MH, Krol D, Biel N, Ricks TK, Fu W, Hamed S, Li F, Sun JJ, Fan J, Schuck R, Grimstein M, Tang L, Kalavar S, Abukhdeir A, Pathak A, Ghosh S, Bulatao I, Tilley A, Pierce WF, Mixter BD, Tang S, Pazdur R, Kluetz P, Amiri-Kordestani L (2024) US food and drug administration approval summary: elacestrant for estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer. J Clin Oncol 42:1193\u20131201. https:\/\/doi.org\/10.1200\/jco.23.02112","journal-title":"J Clin Oncol"},{"key":"1583_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.576","volume":"34","author":"W Shen","year":"2023","unstructured":"Shen W, Hu X, Zhang J, Cao J, Yao H, Wang X, Chen Y, Du Y, Tao Z, Wang L, Hu C, Li C (2023) 399P results from a first-in-human phase Ia\/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2- advanced breast cancer (ABC). Ann Oncol 34:S349. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.576","journal-title":"Ann Oncol"},{"key":"1583_CR136","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/jco.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon DJ, Di\u00e9ras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-Macgregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS (2024) Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol 42:994\u20131000. https:\/\/doi.org\/10.1200\/jco.23.00137","journal-title":"J Clin Oncol"},{"issue":"6","key":"1583_CR137","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Mart\u00edn M, Nusch A, Sonke GS, De La Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G (2020) Overall survival with Ribociclib plus Fulvestrant in advanced breast cancer. N Engl J Med 382(6):514\u2013524. https:\/\/doi.org\/10.1056\/NEJMoa1911149","journal-title":"N Engl J Med"},{"key":"1583_CR138","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A (2020) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6:116\u2013124. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4782","journal-title":"JAMA Oncol"},{"key":"1583_CR139","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1538-7445.AM2021-44","volume":"81","author":"LB Snyder","year":"2021","unstructured":"Snyder LB, Flanagan JJ, Qian Y, Gough SM, Andreoli M, Bookbinder M, Cadelina G, Bradley J, Rousseau E, Chandler J, Willard R, Pizzano J, Crews CM, Crew AP, Houston J, Moore MD, Peck R, Taylor I (2021) Abstract 44: the discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer. Cancer Res 81:44\u201344. https:\/\/doi.org\/10.1158\/1538-7445.AM2021-44","journal-title":"Cancer Res"},{"key":"1583_CR140","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"24","key":"1583_CR141","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1200\/jco.22.02746","volume":"41","author":"SM Tolaney","year":"2023","unstructured":"Tolaney SM, Chan A, Petrakova K, Delaloge S, Campone M, Iwata H, Peddi PF, Kaufman PA, De Kermadec E, Liu Q, Cohen P, Paux G, Wang L, Tern\u00e8s N, Boitier E, Im SA (2023) AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. J Clin Oncol 41(24):4014\u20134024. https:\/\/doi.org\/10.1200\/jco.22.02746","journal-title":"J Clin Oncol"},{"key":"1583_CR142","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2024.13268","author":"M Toumba","year":"2024","unstructured":"Toumba M, Kythreotis A, Panayiotou K, Skordis N (2024) Estrogen receptor signaling and targets: bones, breasts and brain (Review). Mol Med Rep. https:\/\/doi.org\/10.3892\/mmr.2024.13268","journal-title":"Mol Med Rep"},{"issue":"3","key":"1583_CR143","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/2159-8290.Cd-15-1523","volume":"7","author":"W Toy","year":"2017","unstructured":"Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S, Katzenellenbogen JA, Greene G, Baselga J, Chandarlapaty S (2017) Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov 7(3):277\u2013287. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-1523","journal-title":"Cancer Discov"},{"issue":"7","key":"1583_CR144","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1158\/1078-0432.Ccr-24-2460","volume":"31","author":"M Vidal","year":"2025","unstructured":"Vidal M, Falato C, Pascual T, Sanchez-Bayona R, Mu\u00f1oz-Mateu M, Cebrecos I, Gonzalez-Farr\u00e9 X, Cortadellas T, Margel\u00ed Vila M, Luna MA, Siso C, Amillano K, Galv\u00e1n P, Bergamino MA, Ferrero-Cafiero JM, Salvador F, Espinosa Guerrero A, Pare L, Sanfeliu E, Prat A, Bellet M (2025) Elacestrant in women with estrogen receptor-positive and HER2-negative early breast cancer: results from the preoperative window-of-opportunity ELIPSE trial. Clin Cancer Res 31(7):1223\u20131232. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-2460","journal-title":"Clin Cancer Res"},{"key":"1583_CR145","doi-asserted-by":"publisher","first-page":"PD13-01","DOI":"10.1158\/1538-7445.SABCS22-PD13-01","volume":"83","author":"M Vidal","year":"2023","unstructured":"Vidal M, Pascual T, Falato C, Sanchez-Bayona R, Mu\u00f1oz M, Cerbrecos I, Gonzalez-Farr\u00e9 X, Cortadellas T, Margel\u00ed M, Luna MA, Siso C, Amillano K, Galv\u00e1n P, Salvador F, Espinosa A, Par\u00e9 L, Sanfeliu E, Prat A, Ezquerra MB (2023) Abstract PD13-01: PD13-01 elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trial. Cancer Res 83:PD13-01-PD13-01. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-PD13-01","journal-title":"Cancer Res"},{"key":"1583_CR146","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, Mccaskill-Stevens W, Ford LG, Jordan VC, Wolmark N (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Jama 295:2727\u201341. https:\/\/doi.org\/10.1001\/jama.295.23.joc60074","journal-title":"Jama"},{"key":"1583_CR147","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/1940-6207.Capr-10-0076","volume":"3","author":"VG Vogel","year":"2010","unstructured":"Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr., Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, Mccaskill-Stevens W, Ford LG, Jordan VC, Wolmark N (2010) Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res 3:696\u2013706. https:\/\/doi.org\/10.1158\/1940-6207.Capr-10-0076","journal-title":"Cancer Prev Res"},{"key":"1583_CR148","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/bctt.S432526","volume":"15","author":"J Wang","year":"2023","unstructured":"Wang J, Wu SG (2023) Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives. Breast cancer (Dove Medical Press) 15:721\u2013730. https:\/\/doi.org\/10.2147\/bctt.S432526","journal-title":"Breast cancer (Dove Medical Press)"},{"key":"1583_CR149","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2174\/138955709789055207","volume":"9","author":"T Wang","year":"2009","unstructured":"Wang T, You Q, Huang FS, Xiang H (2009) Recent advances in selective estrogen receptor modulators for breast cancer. Mini Rev Med Chem 9:1191\u2013201. https:\/\/doi.org\/10.2174\/138955709789055207","journal-title":"Mini Rev Med Chem"},{"issue":"4","key":"1583_CR150","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s10555-022-10066-y","volume":"41","author":"Y Wang","year":"2022","unstructured":"Wang Y, Tang SC (2022) The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options. Cancer Metastasis Rev 41(4):975\u2013990. https:\/\/doi.org\/10.1007\/s10555-022-10066-y","journal-title":"Cancer Metastasis Rev"},{"key":"1583_CR151","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1158\/1078-0432.Ccr-15-0360","volume":"21","author":"SE Wardell","year":"2015","unstructured":"Wardell SE, Ellis MJ, Alley HM, Eisele K, Vanarsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, Mcdonnell DP, Li S (2015) Efficacy of SERD\/SERM hybrid-CDK4\/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer. Clin Cancer Res 21:5121\u20135130. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-0360","journal-title":"Clin Cancer Res"},{"key":"1583_CR152","doi-asserted-by":"publisher","first-page":"S479","DOI":"10.1016\/j.annonc.2023.09.1872","volume":"34","author":"J Wu","year":"2023","unstructured":"Wu J, Zhang J, Meng Y, Du Y, Liu X, Mu Y, Zhang Y, Wang J, Xin W, Zhu X (2023) 686P phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+\/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC). Ann Oncol 34:S479. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1872","journal-title":"Ann Oncol"},{"key":"1583_CR153","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.molcel.2005.04.014","volume":"18","author":"YL Wu","year":"2005","unstructured":"Wu YL, Yang X, Ren Z, Mcdonnell DP, Norris JD, Willson TM, Greene GL (2005) Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 18:413\u201324. https:\/\/doi.org\/10.1016\/j.molcel.2005.04.014","journal-title":"Mol Cell"},{"key":"1583_CR154","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1021\/acs.jmedchem.5b01276","volume":"59","author":"R Xiong","year":"2016","unstructured":"Xiong R, Patel HK, Gutgesell LM, Zhao J, Delgado-Rivera L, Pham TND, Zhao H, Carlson K, Martin T, Katzenellenbogen JA, Moore TW, Tonetti DA, Thatcher GRJ (2016) Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer. J Med Chem 59:219\u2013237. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01276","journal-title":"J Med Chem"},{"key":"1583_CR155","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10552-011-9729-4","volume":"22","author":"L Yaghjyan","year":"2011","unstructured":"Yaghjyan L, Colditz GA (2011) Estrogens in the breast tissue: a systematic review. Cancer Causes Control 22:529\u201340. https:\/\/doi.org\/10.1007\/s10552-011-9729-4","journal-title":"Cancer Causes Control"},{"key":"1583_CR156","first-page":"7025","volume":"61","author":"X Yang","year":"2001","unstructured":"Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61:7025\u20139","journal-title":"Cancer Res"},{"key":"1583_CR157","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910638","volume":"11","author":"L Ye","year":"2019","unstructured":"Ye L, Lin C, Wang X, Li Q, Li Y, Wang M, Zhao Z, Wu X, Shi D, Xiao Y, Ren L, Jian Y, Yang M, Ou R, Deng G, Ouyang Y, Chen X, Li J, Song L (2019) Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer. EMBO Mol Med 11:e10638. https:\/\/doi.org\/10.15252\/emmm.201910638","journal-title":"EMBO Mol Med"},{"key":"1583_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-017-0053-3","volume":"4","author":"SLH Yeruva","year":"2018","unstructured":"Yeruva SLH, Zhao F, Miller KD, Tevaarwerk AJ, Wagner LI, Gray RJ, Sparano JA, Connolly RM (2018) E2112: randomized phase iii trial of endocrine therapy plus entinostat\/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer 4:1. https:\/\/doi.org\/10.1038\/s41523-017-0053-3","journal-title":"NPJ Breast Cancer"},{"key":"1583_CR159","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1021\/acsptsci.2c00109","volume":"5","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhang Z, Xue X, Fan T, Tan C, Liu F, Tan Y, Jiang Y (2022) PROTAC degrader of estrogen receptor \u03b1 targeting DNA-binding domain in breast cancer. ACS Pharmacol Transl Sci 5:1109\u20131118. https:\/\/doi.org\/10.1021\/acsptsci.2c00109","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1583_CR160","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/jme-15-0310","volume":"57","author":"H Zhao","year":"2016","unstructured":"Zhao H, Zhou L, Shangguan AJ, Bulun SE (2016) Aromatase expression and regulation in breast and endometrial cancer. J Mol Endocrinol 57:R19-33. https:\/\/doi.org\/10.1530\/jme-15-0310","journal-title":"J Mol Endocrinol"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01583-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-025-01583-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01583-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:35:33Z","timestamp":1764952533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-025-01583-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":161,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1007\/s12272-025-01583-9","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,16]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}